March 17, 2026 -- Pharmacosmos today announced the initiation of a phase III, randomised, double-blind, placebo-controlled, multicentre clinical trial evaluating the efficacy and safety of trilaciclib in participants with limited-stage small cell lung cancer. The study is being conducted at clinical sites in the United States, EU and the United Kingdom. The trial will compare trilaciclib with placebo when administered prior to standard chemoradiotherapy and is designed to assess whether trilaci

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026 At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity and Immunoglobulin G Immune Responses for All 31 Serotypes and Was Observed to be Well Tolerated with a Safety Pro to Prevnar 20® Results Fu

March 17, 2026 -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, today announced a strategic manufacturing collaboration to support gene therapy programs using Apertura's TfR1 CapX, a novel AAV capsid that targets human Transferrin Receptor 1 (hTfR1) to cross the blood-

March 17, 2026 -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its first-in-class investigational drug Pidnarulex (CX-5461) has demonstrated a significant research breakthrough in the field of photodynamic therapy (PDT). The research findings have been selected for presentation at the 2026 Annual Meeting of the American Association for Cancer Resea

March 17, 2026 -- Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurologic diseases, today announced that Tien Dam, MD, Chief Medical Officer, will present interim data from the Company's ongoing Phase 1 clinical trial of BT-267, its novel, brain-penetrant leucine-rich repeat kinase 2 (LRRK2) inhibitor, at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026), being

March 17, 2026 – iDEL Therapeutics today announced the closing of a EUR 9 million seed financing, establishing its operations and leadership team. The company is pioneering a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells. iDEL’s new approach is compatible with both large and small molecules and aims to unlock historically undruggable intracellular targets and broaden therapeutic windows across cancer indications. The financing was led by BiomedVC wit

KERENDIA ® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline to Month 32 – a surrogate endpoint for slowing kidney disease progression 1 FIND-CKD is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpoint, adding to a clinical trial program of more than 20,000 patients across multiple patient populations with heart and kidney diseases FIND-

Enrollment begins in Switzerland as the company continues to activate clinical sites beyond the U.S. market March 16, 2026 -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first European participant has been randomized in the company's Phase 2 GALAXY trial. GALAXY is a global Phase 2 clinical trial designed to evaluate the efficacy and safety of xelafaslatide (for

AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available in the United States The launch of AVTOZMA SC further diversifies Celltrion's immunology portfolio beyond TNF-alpha and IL-12/23 inhibitors providing a broader range of treatment solutions for immune-mediated inflammatory diseases March 16, 2026 -- Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) subcuta

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related complications, and modulation of disease-relevant biomarkers March 16, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerativ